News und Analysen
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Agilent’s 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals
Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company’s work supporting customers with their sustainability initiatives while advancing its own internal
EQS-News: Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
EQS-Adhoc: MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
EQS-News: MediClin AG: Higher demand for medical, therapeutic and nursing services led to an increase in sales and earnings in the Group
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received
Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Dexcom Reports Second Quarter 2023 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023.
Second Quarter 2023 Financial Highlights:
-
Revenue grew 25% versus the same
Acadia Healthcare Reports Second Quarter 2023 Results and Raises 2023 Guidance
Acadia Healthcare Company, Inc. (“Acadia”) (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2023.
Second Quarter and Recent Highlights
-
Revenue totaled
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Novocure Reports Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company (AGM)
Chemed Reports Second-Quarter 2023 Results
Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest
ICON Reports Second Quarter 2023 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2023.
CEO, Dr
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process
IMV Inc. (the “Company” or “IMV”), recently announced an update on the Sales and Investment Solicitation Process (the “SISP”) implemented as part of its ongoing proceedings under the Companies'
LivaNova Reports Second-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance.
Financial Summary and
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Formycon reports on the regular Annual General Meeting
Cosmo presents strong H1 2023 operational and financial results
QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Evolva receives approval for Veri-teTM Resveratrol in Taiwan